Metastatic Liver Cancer Clinical Trial
Official title:
A Single Center, Multi Cohort, Phase I Basket Trial of the Safety and Efficacy of Camrelizumab in Combination With Bevacizumab and HAIC for Metastatic Liver Cancer After Standard Treatment Failure
This is a single center, multi-cohort, phase I basket trial to evaluate the safety and efficacy of camrelizumab in combination with bevacizumab and HAIC for metastatic liver cancer after standard treatment failure
For patients with advanced primary liver cancer, immunotherapy combined anti-angiogenic therapy has gradually become the first-line standard treatment. However, for metastatic liver cancer, especially after first-line treatment failure, the current treatment options are mostly systemic chemotherapy, and there is still a lack of effective treatment methods. Compared with systemic chemotherapy, HAIC has a higher objective response rate and survival rate, and the incidence of adverse reactions is lower. At the same time, PD-1 combined with chemotherapy has become the first-line standard treatment for many cancers; referring to the expert consensus on liver metastasis of solid tumors and ongoing clinical research, the "PD-1 + anti-angiogenesis + HAIC" regimen can be used as a new research direction for posterior treatment for metastatic liver cancer. In view of the failure of first-line chemotherapy, how to find effective chemotherapy drugs has become a top priority. HAIC guided by genetic testing may be able to screen out effective chemotherapy drugs This study is an open-label, single-center, multi-cohort, phase I basket trial designed to explore safety and efficacy of "camrelizumab + bevacizumab + HAIC guided by genetic testing" for metastatic liver cancer after standard treatment failure ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04970212 -
Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
|
||
| Recruiting |
NCT04616495 -
Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases
|
||
| Terminated |
NCT03349255 -
Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
|
Phase 1 | |
| Completed |
NCT02201797 -
Reproducibility and Repeatability of Multifunctional MRI Biomarkers of the Body
|
N/A | |
| Recruiting |
NCT03965546 -
ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer
|
Early Phase 1 | |
| Terminated |
NCT03998033 -
Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma
|
Phase 1 | |
| Not yet recruiting |
NCT04825470 -
Liver Transplantation for Unresectable GIST Liver Metastases
|
N/A | |
| Recruiting |
NCT04864054 -
T-Cell Therapy (ECT204) in Adults With Advanced HCC
|
Phase 2 | |
| Recruiting |
NCT05913141 -
PDO/PDO-TIL/PDOTS for Drug Screen
|
||
| Not yet recruiting |
NCT05582018 -
Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures
|
N/A | |
| Recruiting |
NCT01895010 -
Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE
|
Phase 2 | |
| Withdrawn |
NCT05641922 -
Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures (PANORAMA2)
|
N/A | |
| Recruiting |
NCT04634357 -
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04708483 -
DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Comparison With Morphologic Criteria
|
N/A | |
| Terminated |
NCT02787954 -
Prospective Tumor Response Evaluation
|
||
| Completed |
NCT04513457 -
Chemotherapy for Resectable Colorectal Liver Metastases
|
||
| Recruiting |
NCT01442324 -
Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma
|
N/A | |
| Completed |
NCT03888859 -
ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma
|
Early Phase 1 | |
| Recruiting |
NCT05240950 -
Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases
|
Phase 1 | |
| Not yet recruiting |
NCT05986383 -
Multi-center Clinical Study on the Decision Tree of Precision Hepatectomy in China Precision Hepatectomy Decision Tree
|